This description refers to stimulating soluble guanylate cyclase (SGC), Pharmaceutical formulations containing same and its usesAlone or in combination with one or more additional agents, for the treatment of various diseases.Where appropriate, an increase of the concentration of nitric oxide (no) and \/ or an increase in the concentration of cyclic guanosine monophosphate (cGMP) guanosín, or a positive Regulation of The Pathway.Claim 1: a compound of formula (1) or a pharmaceutically acceptable Salt of this,Wherein: The Rings and form the core of the Molecule and aromatic each occurrence of X and y is chosen independently of N or C where a maximum of 4 aparicioneS of X and y are simultaneously N W (i) is absent, with JB in direct connection with the carbon Atom that has two groups J,Each J is selected independently from Hydrogen or MethylN is 1 and JB is an optionally substituted by alkyl Chain c₁₋₇ until 9 appearances of Fluorine or (ii) is a Ring b which is a phenylA c₃₋₇ cycloalkyl Ring or a heteroaryl Ring of 5 or 6 members, containing 1 or 2 nitrogen Atoms of the ring, whereWhen the ring is the Ring B of 5 or 6 members or heteroaryl phenyl J each is independently selected from Hydrogen or Methyl and N is an integer between 0 and 3 is selected and caJB is independently selected from Halogen, - CN, an aliphatic c₁₋₆ Orb, or a ring cicloalifático c₃₋₈ and where,When the Ring B is the c₃₋₇ cycloalkyl Ring each J is Hydrogen n is an integer between 0 and 3 are selected and each independently JB is selected from Halogen, CNAn aliphatic or c₁₋₆ - orb¹ where every JB is an aliphatic c₁₋₆ and every JB is a ring cicloalifático c₃₋₈ replaced optionally and independently with up to 3 r³ appearances of each RBIs selected independently from a c₁₋₆ aliphatic Ring or a cicloalifático c₃₋₈ where the RB is replaced optionally and independently with up to 3 appearances r³ᵃ eachB¹ independently selected from Hydrogen,A c₁₋₆ aliphatic Ring or a cicloalifático c₃₋₈ where each of sa
